Hemopressin (rat)

Product Name: Hemopressin (rat)

CAS No: 568588-77-2

Purity: 95%

Molar Mass: 1088.3

Chemical Formula: C53H77N13O12

Storage: Store at -20 degrees Celsius

Sequence: PVNFKFLSH

Application:

Hemopressin is a bioactive peptide derived from the alpha-chain of hemoglobin, known for its role as an inverse agonist of cannabinoid receptors, particularly CB1. By binding to these receptors, hemopressin reduces the activity of the endocannabinoid system, which is implicated in pain modulation, appetite control, and energy balance. In pharmaceutical research, hemopressin is explored for its potential therapeutic applications in conditions such as obesity, pain, and metabolic disorders. Its unique mechanism of action makes it a valuable tool for studying cannabinoid receptor functions and developing novel treatments targeting these pathways.

Current Research:

Hemopressin, a nonapeptide derived from the α1-chain of hemoglobin, has emerged as a significant molecule in the field of cannabinoid research. It is recognized as an inverse agonist or antagonist of the cannabinoid type 1 receptor (CB1R), modulating endocannabinoid signaling pathways. Its unique mode of action distinguishes it from other cannabinoid receptor ligands, making it a valuable tool in understanding cannabinoid-related physiology and pathology.

Mechanism of Action
Hemopressin binds selectively to CB1R, exerting inhibitory effects on receptor activity. Unlike traditional CB1R agonists, it does not induce psychotropic effects, making it an attractive candidate for therapeutic applications targeting the endocannabinoid system without central nervous system side effects.

Applications in Research
Pain and Inflammation
Hemopressin’s modulation of CB1R activity has been investigated for its potential to alleviate pain and reduce inflammation. Studies suggest that it may counteract hyperactive endocannabinoid signaling, offering a novel approach to managing chronic pain and inflammatory disorders.

Metabolic Disorders
By antagonizing CB1R, hemopressin has shown promise in regulating energy balance, appetite, and glucose metabolism. This positions it as a potential therapeutic agent for obesity and metabolic syndrome, conditions closely linked to dysregulated cannabinoid signaling.

Neurological Disorders
Hemopressin’s neuroprotective effects, mediated through CB1R modulation, have sparked interest in its application for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its ability to regulate neurotransmitter release and protect against excitotoxicity is a focus of ongoing research.

Addiction Studies
The peptide’s inverse agonism at CB1R has potential implications for addiction research, particularly in reducing dependence on substances that act through the endocannabinoid system.

Future Directions
Current research is focused on developing hemopressin analogs with enhanced stability, bioavailability, and receptor specificity. These advances aim to refine its therapeutic potential while minimizing off-target effects.

For researchers, hemopressin offers a unique perspective on cannabinoid signaling, providing opportunities to explore innovative treatments for pain, metabolic disorders, and neurological diseases. Its distinct pharmacological profile underscores its importance in peptide-based drug discovery.

Reference:

Fogaça, M. V., Sonego, A. B., Rioli, V., Gozzo, F. C., Dale, C. S., Ferro, E. S., & Guimaraes, F. S. (2015). Anxiogenic-like effects induced by hemopressin in rats. Pharmacology Biochemistry and Behavior, 129, 7-13.